Intelligence Feed event · Equity · 2026-09-17

    Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against Wegovy

    Question

    Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against Wegovy

    Direct answer

    Eli Lilly is advancing in the oral metabolic treatment category, with US prescriptions for its oral GLP-1 drug Foundayo reaching 47,500. While Novo Nordisk continues to lead the oral category with 183,000 active Wegovy pill prescriptions, Lilly's volume ramp indicates accelerating physician adoption. Eli Lilly currently commands an estimated 60% share of the broader injectable and oral US weight-loss drug market. Trajectory shifts in oral dosing convenience are expected to dictate competitive market share balances across commercial payer formularies.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-17
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against Wegovy”, revision 1, evidence through 2026-09-17. https://marketontology.com/market-events/2026-09-17/eli-lilly-expands-us-oral-glp-1-foundayo-prescriptions-to-47-5k-against-wegovy-dbda91

    EQUITY
    Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against Wegovy
    Eli Lilly is advancing in the oral metabolic treatment category, with US prescriptions for its oral GLP-1 drug Foundayo reaching 47,500. While Novo Nordisk continues to lead the oral category with 183,000 active Wegovy pill prescriptions, Lilly's volume ramp indicates accelerating physician adoption. Eli Lilly currently commands an estimated 60% share of the broader injectable and oral US weight-loss drug market. Trajectory shifts in oral dosing convenience are expected to dictate competitive market share balances across commercial payer formularies.
    LLYNVO
    Impact
    72
    SEP 17
    SIG
    83%
    LLYNVO
    Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against Wegovy
    Eli Lilly is advancing in the oral metabolic treatment category, with US prescriptions for its oral GLP-1 drug Foundayo reaching 47,500. While Novo Nordisk continues to lead the oral category with 183,000 active Wegovy pill prescriptions, Lilly's volume ramp indicates accelerating physician adoption. Eli Lilly currently commands an estimated 60% share of the broader injectable and oral US weight-loss drug market. Trajectory shifts in oral dosing convenience are expected to dictate competitive market share balances across commercial payer formularies.
    → Prescription share gains in oral formulations expand Eli Lilly's market capture in metabolic therapeutics, influencing revenue mix versus Novo Nordisk.
    Impact
    Eli Lilly is advancing in the oral metabolic treatment category, with US prescriptions for its oral GLP-1 drug Foundayo reaching 47,500. While Novo Nordisk continues to lead the oral category with 183,000 active Wegovy pill prescriptions, Lilly's volume ramp indicates accelerating physician adoption. Eli Lilly currently commands an estimated 60% share of the broader injectable and oral US weight-loss drug market. Trajectory shifts in oral dosing convenience are expected to dictate competitive market share balances across commercial payer formularies.
    Affected
    LLYNVO
    Transmission
    Prescription share gains in oral formulations expand Eli Lilly's market capture in metabolic therapeutics, influencing revenue mix versus Novo Nordisk.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYcommercial market share expansion in oral metabolic treatmentsUp1-3mLilly holds 60% US weight loss share and reached 47,500 prescriptions for Foundayo oral GLP-1.
    NVOcompetitive pricing and volume pressure in oral anti-obesity categoryMixed1-3mNovo leads the oral segment with 183,000 Wegovy pill scripts as Lilly closes the gap.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    NVOMixed43.19 2026-09-17+0.12%-10.58%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month